|
#2
22.11.2006, 23:10
|
|||
|
|||
|
Expert consensus document on b-adrenergic receptor blockers
The Task Force on Beta-Blockers of the European Society of Cardiology European Heart Journal (2004) 25, 1341–1362 [Ссылки доступны только зарегистрированным пользователям ] "The effect on prognosis in patients with stable angina has not been specifically studied in large trials, and most of the information comes from studies in the prethrombolytic era, when myocardial revascularisation was more restricted. A history of angina has, however, been present in about 1/3 of patients recruited in post infarction studies with b-blockers. The b-blockers pooling project67 reported a highly significant reduction in mortality in this subgroup, and it seems reasonable to assume that b-blockers have the potential to prevent death, especially sudden cardiac death, and myocardial infarction even when there has been no prior infarction.[53;57;79] 
|
|
#3
22.11.2006, 23:17
|
|||
|
|||
|
"The effects of b-blockers in patients with stable angina without prior MI or hypertension have been investigated in some randomised controlled trials. In the Total Ischaemic Burden European Trial (TIBET)[104], no difference
was found between atenolol and nifedipine, and in the Angina Prognosis Study in Stockholm (APSIS)[105] the clinical outcome was similar in the groups treated with metoprolol and verapamil. In the Atenolol Silent Ischaemia Study (ASIST),[91] in patients with mild angina, atenolol decreased ischaemic episodes at 6 weeks as compared with placebo and after 1 year there was an improvement in the cardiovascular combined outcomes. In the Total Ischaemic Burden Bisoprolol Study (TIBBS)[106] bisoprolol was more effective than nifedipine in reducing the number and duration of ischaemic episodes in patients with stable angina. In the International Multicenter Angina Exercise (IMAGE) trial,[107] metoprolol was more effective than nifedipine in controling exercise induced ischaemia."
|
Комбинированный вид
